Literature DB >> 677860

Azlocillin and mezlocillin: new ureido penicillins.

K P Fu, H C Neu.   

Abstract

The activity of azlocillin and mezlocillin, new semisynthetic ureido penicillins, was investigated and compared with that of other known beta-lactam antibiotics. At a concentration of 25 mug/ml, azlocillin inhibited 74% of Enterobacter, 97% of Proteus mirabilis, 64% of Citrobacter, 91% of Pseudomonas aeruginosa, and 82% of Bacteroides strains tested. Mezlocillin inhibited 86% of Shigella, 96% of Enterobacter, 80% of indole-positive Proteus, 88% of Bacteroides, and 63% of Pseudomonas strains tested. Azlocillin was more active against Pseudomonas than was ticarcillin, carbenicillin, or mezlocillin. Mezlocillin was more active than carbenicillin and ampicillin against Escherichia coli, Klebsiella, Enterobacter, Citrobacter, Acinetobacter, Serratia, and Bacteroides. Azlocillin and mezlocillin were less active than cefazolin against beta-lactamase-producing E. coli and Klebsiella strains but more active than cefazolin against Enterobacter, indole-positive Proteus, Acinetobacter, Citrobacter, and Serratia strains. Both compounds showed activity equivalent to that of cefoxitin against Bacteroides isolates. Both agents were destroyed by many of the beta-lactamases from gram-negative organisms.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 677860      PMCID: PMC352365          DOI: 10.1128/AAC.13.6.930

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Microiodometric determination of beta-lactamase activity.

Authors:  R B Sykes; K Nordström
Journal:  Antimicrob Agents Chemother       Date:  1972-02       Impact factor: 5.191

2.  The hemostatic defect produced by carbenicillin.

Authors:  C H Brown; E A Natelson; W Bradshaw; T W Williams; C P Alfrey
Journal:  N Engl J Med       Date:  1974-08-08       Impact factor: 91.245

3.  Carbenicillin and hypokalemia.

Authors:  J Klastersky; B Vanderklen; D Daneau; M Mathiew
Journal:  Ann Intern Med       Date:  1973-05       Impact factor: 25.391

4.  Purification and characterization of penicillinases from Salmonella typhimurium and Escherichia coli.

Authors:  H C Neu; E B Winshell
Journal:  Arch Biochem Biophys       Date:  1970-08       Impact factor: 4.013

5.  In vitro study of netilmicin compared with other aminoglycosides.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

6.  Comparative in vitro activity and clinical pharmacology of ticarcillin and carbenicillin.

Authors:  H C Neu; G J Garvey
Journal:  Antimicrob Agents Chemother       Date:  1975-10       Impact factor: 5.191

7.  Altered penicillin-binding components in penicillin-resistant mutants of Bacillus subtilis.

Authors:  C E Buchanan; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1976-06       Impact factor: 11.205

8.  In vitro synergistic effect of netilmicin, a new aminoglycoside antibiotic.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

  8 in total
  41 in total

1.  Activity of beta-lactam antibiotics against Pseudomonas aeruginosa carrying R plasmids determining different beta-lactamases.

Authors:  G A Jacoby; L Sutton
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

2.  Agar disk diffusion susceptibility characteristics of azlocillin, carbenicillin, mezlocillin, piperacillin, and ticarcillin.

Authors:  D Phaneuf; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

3.  Serum bactericidal activity of mezlocillin, ceftazidime, mezlocillin/ceftazidime and mezlocillin/amikacin against Klebsiella pneumoniae and Pseudomonas aeruginosa.

Authors:  Y Van Laethem; J Klastersky
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

4.  Concentrations of mezlocillin in the serum, heart valves, muscle and subcutaneous tissue of patients undergoing open-heart surgery.

Authors:  F Daschner; H M Just; I Kappstein; H Spillner; V Schlosser
Journal:  Infection       Date:  1985 Jul-Aug       Impact factor: 3.553

5.  Pharmacokinetics and bacteriological efficacy of mezlocillin in experimental Escherichia coli and Listeria monocytogenes meningitis.

Authors:  C Odio; M L Thomas; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

6.  Diagnosis and therapy of anaerobic infections in childhood.

Authors:  R Roos; W Marget
Journal:  Infection       Date:  1980       Impact factor: 3.553

7.  In vitro activities of ureidopenicillins alone and in combination with amikacin and three cephalosporin antibiotics.

Authors:  J A Moody; L R Peterson; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

8.  Determination of the ureidopenicillins azlocillin, mezlocillin and bay K 4999 in plasma by high performance liquid chromatography.

Authors:  U Gundert-Remy; J X De Vries
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

9.  The pharmacokinetics of furazlocillin in healthy humans.

Authors:  P H Hinderling; U Gundert-Remy; D Förster; W Gau
Journal:  J Pharmacokinet Biopharm       Date:  1983-02

Review 10.  Penicillins. A current review of their clinical pharmacology and therapeutic use.

Authors:  Dilip Nathwani; Martin J Wood
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.